Ugur Sahin
乌尔·沙欣
MD, PhD
Co-Founder, CEO & Chief Medical Officer, BioNTech SE; Professor of Experimental Oncology拜恩泰科联合创始人、首席执行官兼首席医疗官；实验肿瘤学教授
👥Biography 个人简介
Ugur Sahin is the co-founder and CEO of BioNTech SE, and a pioneer of mRNA-based cancer immunotherapy. He led development of the individualized neoantigen vaccine mRNA-4157 (V940), demonstrating landmark efficacy in melanoma in the KEYNOTE-942 trial. His foundational mRNA platform research transformed both oncology and pandemic vaccine response.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Personalized mRNA Neoantigen Cancer Vaccine (mRNA-4157/V940)
Invented and led clinical development of mRNA-4157/V940 in partnership with Merck; KEYNOTE-942 phase 2b trial showed 44% reduction in recurrence/death risk in high-risk melanoma when combined with pembrolizumab.
mRNA Platform Technology for Oncology
Established BioNTech's individualized cancer immunotherapy (iNeST) platform, encoding up to 34 patient-specific neoantigen mutations per vaccine and enabling rapid, scalable GMP manufacturing of personalized mRNA constructs.
BNT111 and Shared-Antigen mRNA Vaccines
Advanced BNT111 fixed-neoantigen mRNA vaccine for melanoma into phase 2 trials, demonstrating that shared tumor antigens encoded in lipid nanoparticle-formulated mRNA can elicit durable T cell responses in patients.
Representative Works 代表性著作
Individualized vaccines of RNA neoepitopes as immunotherapy for patients with melanoma
Nature (2017)
Landmark first-in-human trial of personalized mRNA neoantigen vaccines in melanoma patients; demonstrated induction of neoantigen-specific T cell responses and preliminary anti-tumor activity.
mRNA-based therapeutics — developing a new class of drugs
Nature Reviews Drug Discovery (2014)
Foundational review establishing mRNA as a therapeutic class; framework paper cited extensively in cancer vaccine and infectious disease mRNA development.
Adjuvant pembrolizumab plus individualized neoantigen therapy versus pembrolizumab alone in resected melanoma (KEYNOTE-942)
The Lancet (2023)
Phase 2b randomized trial demonstrating that mRNA-4157/V940 + pembrolizumab reduced risk of recurrence or death by 44% vs pembrolizumab alone in stage III/IV melanoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 乌尔·沙欣 的研究动态
Follow Ugur Sahin's research updates
留下邮箱，当我们发布与 Ugur Sahin（BioNTech SE / University Medical Center of the Johannes Gutenberg University Mainz）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment